undamentalytics Newsletter
Sign in

Agios Pharmaceuticals, Inc. income statement

In fiscal 2025, Agios Pharmaceuticals, Inc. reported revenue of $54.0m, up 48.0% on the year before, operating income of −$472m (a -873.9% margin) and net income of −$413m, or −$7.12 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2011Dec 20112012Dec 20122013Dec 20132014Dec 20142015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue2225266559704394118001427365498
Cost of revenue—————00110023468
Gross profit—————704393117001324324890
Research and development314155100142220293341214221257280296301340357
Selling, general and administrative—————5171114102115121122120157180193
General and administrative77101936———————————
Operating income−17−23−39−54−119−201−321−362−316−336−378−389−391−426−472−459
Income before tax−16−23−39−54−118−198−315−346−301−329−357−232−352718−414—
Income tax7−31−000000——0044−1—
Net income−24−20−39−54−118−198−315−346−411−3271,605−232−352674−413−411
Diluted EPS−$8.90−$8.02−$2.83−$1.59−$3.15−$5.07−$6.75−$6.03−$6.86−$4.74$26.55−$4.23−$6.33$11.64−$7.12−$7.01
Diluted shares (average)3m3m15m34m37m39m47m57m60m69m60m55m56m58m58m59m
EBITDA−16−22−37−53−115−195−314−355−308−327−370−381−385−420−467—

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: AGIO vs SEPNAGIO vs KYMRAGIO vs XNCRAGIO vs FDMT

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Agios Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Agios Pharmaceuticals, Inc.